NRX Pharmaceuticals, Inc. - Common Stock NRXP 深 滬
等待開盤 09-25 09:30:00 美东时间
2.99
+0.140
+4.91%
華盛通- 最 高3.18
- 今 開3.03
- 成交量 86.56万股
- 最 低 2.95
- 昨 收 2.85
- 總市值 7107.20万
- 52周最高 6.01
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.10
- 委 比 -32.45%
- 總股本 2376.99万
- 歷史最高 769.90
- 量 比 2.76
- 振 幅 8.07%
- 歷史最低 1.58
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NRx Pharmaceuticals Announces FDA Has Granted Suitability Petition For Its Planned Preservative-Free Ketamine Product Ketafree
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, announced that it was notified yesterday by the United States Food and Drug Administration that a Suitability Petition has been granted
09-24 20:07
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
NRx Pharmaceuticals received FDA approval for its Suitability Petition, enabling it to re-file the Abbreviated New Drug Application (ANDA) for its preservative-free, single-patient dose ketamine product, KETAFREE™. The product addresses the administration's goals of re-shoring critical drugs and removing toxic preservatives. Currently, ketamine is sold with Benzethonium Chloride, a toxic preservative. The Company plans to bring KETAFREE™ to the U...
09-24 12:03
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Nurix Therapeutics and Gilead Sciences have advanced GS-6791, a novel IRAK4 degrader, into clinical testing for inflammatory diseases. Preclinical data, presented at the EADV Congress, demonstrate GS-6791's ability to degrade IRAK4, inhibiting IL-1 and IL-36 responses and reducing disease in a model of atopic dermatitis. Serving as a potent, selective, and oral therapy, GS-6791 has shown promise in treating inflammatory conditions. The ongoing Ph...
09-17 11:00
NRX Pharmaceuticals Completes Acquisition of Dura Medical
NRX Pharmaceuticals ( ($NRXP) ) has issued an update. On September 8, 2025, NRx...
09-13 05:04
NRX Pharmaceuticals Raises $8.8 Million in Stock Offering
An announcement from NRX Pharmaceuticals ( ($NRXP) ) is now available. On Septe...
09-09 05:06
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.
09-08 22:09
NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
NRx Pharmaceuticals' CEO Jonathan Javitt will participate in a fireside chat at H.C. Wainwright’s Global Investment Conference on Sept. 8, 2025. The event will be webcast and available for replay. NRx, focused on NMDA-targeted therapeutics for CNS disorders like suicidal depression, has filed applications for its ketamine-based treatments. Its subsidiary, HOPE Therapeutics, plans to build interventional psychiatry clinics offering ketamine and ot...
09-03 12:03
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital
NRx Pharmaceuticals announced plans to launch HOPE Therapeutics clinics in September 2025, starting with a flagship location in Palm Beach, Florida. The company recently raised $8.8 million from biotech investors. HOPE clinics will combine neuroplastic drugs like ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy to treat suicidal depression, PTSD, and cognitive dysfunction. Matthew Rockefeller joined the HOPE Therapeutics...
09-02 12:41
FDA Grants Fast Track To NRx's NRX-100 For Suicidal Depression; Expanded Access Now Available For Eligible Patients
US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression.NRx Pharmaceuticals is making NRX-100
08-27 20:10
NRx Pharmaceuticals (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
Austin, Texas, United States, August 25th, 2025, FinanceWire NRx Pharmaceutical...
08-25 23:30
